The content on this website is intended solely for veterinarians and other animal health professionals.
By using this website, you confirm that the above applies to you.
Large-scale manufacturing process for Strangvac now secured
The biotechnology company Intervacc has together with 3P Biopharmaceuticals, the contracted manufacturer of Strangvac, secured large-scale production of the vaccine against equine strangles. The technology transfer of manufacturing and the verification of...New CEO appointed for Intervacc – a innovative and expanding vaccine company
Intervacc, a Swedish innovative vaccine company listed on Nasdaq First North, has appointed Andreas Andersson as CEO. The Company thus gains a valuable addition to lead the expansion and strategic development on the growth journey for a new generation of animal health...New supplementary Strangvac study demonstrates immunological memory with long duration
The Swedish biotechnology company Intervacc has now taken another step towards confirming the effect of its vaccine, one of the company’s development development projects, against the infamous streptococcal infection strangles in the horse. A new supplementary...Intervacc recieves funding from Eurostars for further development of vaccine for piglets.
Intervacc has been awarded funding through the Eurostars-2 program for further development of a vaccine against severe infection of piglets caused by Streptococcus suis. The Eurostars-2 program, a part of EU:s Horizon 2020, thus finances approximately 50% of the...Intervacc signs an agreement for future filling and release of Strangvac.
Strangvac® is Intervacc’s vaccine against strangles, which is a very severe and contagious infection in the horse. Intervacc has previously signed an agreement with 3P Biopharmaceuticals in Pamplona, Spain for large-scale commercial production of the components...Nyhetstjänster
